You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱點掃描 | 5家中國藥企獲準仿製默沙東新冠口服藥

uSMART盈立智投1月21日消息,截止發稿,港股三大指數漲跌互現,恆生指數微跌0.35%,報24864.64點,成交額666.55億;恆生科技指下跌0.70%,報5854.27點,成交額182.02億;紅籌指數上漲0.72%報4176.99點,成交額22.87億。

27家藥企獲準仿製默沙東新冠口服藥,27家中5家爲中國藥企,包含有:維亞生物、復星醫藥等。維亞生物早盤高開,近9%,隨後衝高超12%;復星醫藥漲超5%。

藥物板塊內現分化情形,先聲藥業、開拓藥業均跌超5%、君實生物跌超11%、歌禮制藥跌超18%、康希諾跌超8%。

十四五旅遊發展規劃中宣將發展入境旅遊業。攜程漲近9%、同程漲超7%。

酒精飲料續漲,青啤漲超7%、潤啤漲超5%、百威亞太漲超5%。麥格理今日發表研報重申百威亞太【跑贏大市】評級,予30港元目標價。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account